Biotech Values

[DewDiligence]

MNTA M402 description from the 2009 10K report filed today (c/o rkrw on SI):

http://sec.gov/Archives/edgar/data/1235010/000104746910002115/a2197212z10-k.htm (page 9)

M402 is our next most advanced novel HSPG-based product candidate [i.e. M118 is first in line among MNTA’s proprietary compounds] and is engineered to have potent anti-cancer properties and low anticoagulant activity.

HSPGs are complex molecules present in the tumor microenvironment which play a role in the conversion of normal cells into cancerous cells and present growth factors, cytokines, and chemokines necessary for tumor cell growth, migration, and survival. M402 is designed to exploit this biology. Data from preclinical studies have shown that M402 has the potential to modulate angiogenesis and tumor metastasis through a variety of HSPG-binding proteins.

We currently have plans to advance M402 into human clinical trials in the first half of 2011 [#msg-46537561, bottom].

With a little added color, the above is essentially the same rationale for M402 that Craig Wheeler has given on CC’s (#msg-37030489) and MNTA presented at the 2009 AACR conference (#msg-37152092).